The incentive structure for being contact traced recently changed dramatically. Contact tracing traditionally uses quarantine to stop the spread of infectious disease, but at substantial financial, logistical, educational, and social costs. Today, fully vaccinated contacts are no longer required to quarantine in the U.S. and many other countries, but are asked merely to get tested and monitor symptoms. Being traced thus makes early diagnosis of COVID-19 more likely, and with it, earlier treatment that might be more effective. Indeed, post-exposure prophylactic treatment can prevent an initial infection event from progressing to COVID-19 symptoms, preventing both individual disease and community spread. This panel will feature two speakers, one describing clinical data on post-exposure prophylaxis with monoclonal antibodies against COVID-19, the other its epidemiological consequences.